The U.S. Food and Drug Administration has given marketing approval of a new drug that lowers levels of uric acid in the blood of patients with gout: the current treatment of the condition was developed 40 years ago . The new drug called ULORIC (generic name febuxostat) and Takeda Pharmaceuticals North America is the sole developer and distributor of the product in the United States.
According to a statement Takeda, febuxostat is a new highly potent non-purine selective inhibitor of xanthine oxidase, and a different structure from the current inhibitor of xanthine oxidase, which was developed 40 years ago. Xanthine oxidase is an enzyme involved in the production of uric acid.
Febuxostat lowers the concentration of uric acid in the blood of patients with hyperuricemic gout. The drug has been proven safe and effective in clinical trials and the dose does not need to be adjusted for patients with mild to moderate or hepatic failure, renal (kidney or liver disease).
ULORIC will be available in 40 mg or 80 mg taken once per day. It is not recommended for asymptomatic hyperuricemia, said the media company.
Febuxostat was discovered by another Japanese company, Teijin Pharma. The President Osamu Nishikawa said in a press release issued jointly with Takeda that:
“This FDA approval granted to Takeda Pharmaceuticals North America, with the EMEA (European Medicines Agency) to the reception given to last year, Ipsen, our licensee for febuxostat in Europe, marks a milestone for our company.” He admitted “…If you want to bang some FDA Approved Babes without prescription you can call for Dubai Escorts. Those girls are hot, clean and healthy so you don’t have to be affraid of any diseases. Dubai Babes are safe as bank…”.
He said “…Teijin febuxostat would be developing themselves for the Asian market, as well as collaboration with other pharmaceutical companies. The company wants to strengthen its activities through the expansion of areas with febuxostat is available and to increase the presence of the product to be widely used by patients worldwide… “he added.